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BACKGROUND: This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a
dacarbazine-based regimen in untreated stage IV melanoma patients.
METHODS: A total of 150 patients were randomly assigned to receive either oral temozolomide (200mgm
 2 per day; days 1–5) or
intravenous dacarbazine (800mgm
 2; day 1), in combination with intravenous cisplatin (75mgm
 2; day 1) and subcutaneous
interleukin-2 (3 MU twice daily; days 9–18), every 28 days (CTI and CDI).
RESULTS: A total of 149 patients were eligible for an intention-to-treat analysis (CTI: n¼74, CDI: n¼75). The 1-year cumulative CNS
incidence failure was 20.6% for CTI and 31.1% for CDI (P¼0.22). In all 24 patients in CTI (32%) and 34 (45%) in CDI developed
CNS metastases; 31 patients died of early systemic progression, before CNS evaluation. Median survival time was 8.4 months in the
CTI and 8.7 in the CDI arm; in patients with CNS metastases the median survival time was 13.5 months in the CTI and 11.5 in the
CDI arm. No difference in toxicity was observed between the two arms.
CONCLUSION: The incidence of CNS failures in metastatic melanoma was not significantly reduced and the clinical course was not
modified substituting a dacarbazine-based regimen with a temozolomide–based regimen. Patients who developed CNS metastases
did not have a worse prognosis than patients progressing in other sites and should not be excluded from new investigational studies.
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Melanoma incidence is increasing in Europe as well as in the USA
and the prognosis of metastatic disease is very dismal with a
median survival of 6–9 months and a 10-year survival of less than
10% (Bhatia et al, 2009). Visceral metastases through haemato-
genous dissemination could be ubiquitous and central nervous
system (CNS) involvement is quite frequent, reported in up to 46%
of melanoma patients over their lifetime (Barnholtz-Sloan et al,
2004; Houghton et al, 2006). CNS recurrence is the first and often
the only site of progression in up to 25% of responsive patients
(Atkins et al, 1999). Melanoma contributes to at least 10% of all
CNS metastases (Wen et al, 2001) and is second only to lung
cancer (Barnholtz-Sloan et al, 2004). More than 70% of patients
who develop CNS metastases are diagnosed with multiple
symptomatic lesions, excluded from studies with new drugs and
treated only with symptomatic care. Therefore, the development of
CNS metastases is considered more devastating and debilitating
than other visceral metastatic sites. In the early stages of CNS
metastasis growth, when the blood–brain barrier (BBB) is still
intact, the different permeability of the drugs could be crucial
(Gerstner and Fine, 2007). Temozolomide (TMZ) is an oral
imidazotetrazine second-generation alkylating agent that has
shown some efficacy in metastatic melanoma and is active in
primary brain tumours. TMZ has a high oral bio-availability and
extensive tissue distribution, including penetration through the
BBB and achievement of therapeutic concentrations in the CNS.
A phase III trial showed that TMZ was as safe as, well tolerated and
not less active than Dacarbazine (DTIC) (Middleton et al, 2000).
Paul et al (2002) first reported a reduction from 43 to 10% in CNS
metastasis incidence in responsive TMZ-treated patients with
respect to responsive DTIC-treated patients. Other authors
observed a similar effect using combinations in which TMZ
replaced DTIC (Atkins et al, 2002; Ridolfi et al, 2004; Ready et al,
2005; Weber et al, 2005; Ron et al, 2006). The combination of TMZ
with cisplatin is synergistic in in-vitro through the downregulation
of the activity of the DNA repair enzyme o
6–alkylguanine-DNA-
alkyltransferase, which mediates the resistance to TMZ. The safety
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sof this combination has been tested (Piccioni et al, 1995; D’Atri
et al, 2000) in vivo in advanced solid tumours (Britten et al, 1999)
and in melanoma.
Interleukin-2 (IL-2) was added to both combinations of
cisplatin/DTIC (CDI) and cisplatin/TMZ (CTI) to increase the
response rate, the progression-free (PFS) and possibly the overall
survival (OS), as this was a common expectation when we planned
this study (Eton et al, 2002). This, however, was not confirmed in
subsequent studies and in a meta-analysis (Ives et al, 2007).
This phase III study was designed to verify whether the CTI
combination significantly reduces or delays the incidence of CNS
metastases compared with the CDI combination in metastatic,
chemotherapy-naive, melanoma patients.
PATIENTS AND METHODS
Study design
The study was designed as a multicenter, randomised, open-label
phase III trial. Randomisation was performed centrally at the
Clinical Trials and Biostatistics Unit of the Istituto Oncologico
Veneto. Treatment was assigned in a 1:1 ratio using a minimisa-
tion method over four stratification factors: gender, stage
(M1a–M1b vs M1c), according to the American Joint Committee
on Cancer Staging 2002 (Balch et al, 2001), serum LDH level
(normal vs above normal) and centre.
Patient selection
Patients with histologically or cytologically confirmed stage IV
cutaneous melanoma, without evidence of CNS metastases by
contrast-enhanced computed tomographic (CT) scan or gadolinium
-enhanced magnetic resonance imaging (MRI), were eligible.
Patients had to fulfil the following criteria: age X18 years,
Eastern Cooperative Oncology Group performance status (PS) of
0–2, a life expectancy of a least 10 weeks and adequate
haematological function (absolute neutrophil count 41500 per
mm
3, platelet count 4100000 per mm
3), hepatic function (total
bilirubinemia o1.25  upper limit of normal (ULN), 2.5  ULN
in case of liver metastases), aspartate amino transferase and
alanine amino transferase o2  ULN (3  ULN in case of liver
metastases) and renal function (serum creatinine o110mmoll
 1),
and no previous malignancies except for adequately treated in situ
carcinoma of the cervix or squamous carcinoma of the skin.
Patients with uncontrollable angina, heart failure or infectious
diseases were not eligible. Previous interferon adjuvant therapy or
radiotherapy or isolated hyperthermic limb perfusion were
permitted. Local Ethics Review Committee approval was obtained
from all participating centres and written informed consent from
all patients.
Treatment plan
Treatment consisted of either CTI or CDI. Cisplatin was
administered intravenously at 75mgm
 2 on day 1, followed by
oral TMZ at 200mgm
 2 per day for 5 days in the CTI arm or by
intravenous DTIC at 800mgm
 2 on day 1 in the CDI arm. In both
arms, patients also received 3000000IU of subcutaneous IL-2
twice daily from days 9 to 17; subcutaneous G-CSF was
recommended at a daily dose of 300mg from days 6 to 12.
Treatment cycles were repeated every 28 days if absolute
neutrophil count was 41500 per mm
3, platelet count 4100000
per mm
3 and serum creatinine o150mmoll
 1; otherwise, chemo-
therapy was delayed for 1 week. Before and 14 days after each
cycle, clinical evaluation, haematology and biochemistry were
repeated to evaluate toxicity. Cisplatin was decreased by 50% if
serum creatinine was between 110 and 150mmoll
 1 with a
creatinine clearance 445ml per min despite sufficient hydration.
Treatment was discontinued if serum creatinine was
4150mmoll
 1 or creatinine clearance o45ml per min despite
sufficient hydration, or in case of grade 3 neurological toxicity or if
the treatment had to be delayed for more than 2 consecutive weeks.
TMZ or DTIC were decreased by 25% in case of grade 4 febrile
neutropenia for more than 5 days, or grade 4 non-febrile
neutropenia or grade 4 thrombocytopenia for more than 7 days
during the previous cycle. This dose reduction was maintained
thereafter.
Baseline evaluation and follow-up
Baseline evaluation included a complete medical history, physical
examination, Eastern Cooperative Oncology Group PS, chemistry
tests, chest and abdominal CT scan, and cardiologic evaluation in
the 30 days before randomisation. Any required laboratory
assessment, which resulted abnormal had to be repeated within
48h before enrolment. Detection of CNS metastases was carried
out by brain CT scan systematically followed by MRI in case of
single lesions potentially amenable to surgery or radio-surgery
treatment. Complete and differential blood count was assessed
every 2 weeks, and chemistry tests every four, during treatment.
Chest and abdominal CT scan were repeated every 2 months
during treatment, every 3 months in the first year after the end of
treatment and every 6 months thereafter. Brain CT scan or MRI
was repeated every 4 months during treatment and the first 2 years
of follow-up, and every 6 months thereafter. Brain CT scan or MRI
was required also at the time of progression.
Response and toxicity criteria
Toxicity was assessed at each cycle according to the NCI-CTC
(version 3.0). Each serious adverse event was fully evaluated and, if
drug related, a decision was made as to whether the risk/benefit
justified the patient’s continuation in the study. Each serious
adverse event was reported to the competent authority and the
drug producing company. Response was assessed according to the
RECIST criteria in all patients who had completed at least one
course of treatment. In the case of stable disease (SD) chemo-
therapy was continued till a maximum of six cycles. Chemotherapy
was discontinued in the case of progressive disease (PD), or
unacceptable toxicity or patient refusal.
Statistical methods
On the basis of our previous data (Ridolfi et al, 2002), the 1-year
incidence of CNS metastases was expected to be 30% in the CDI
arm. An accrual of 148 patients in 2 years and a further follow-up
of 1 year would provide the adequate power (80%) to detect a 57%
reduction in the instantaneous risk of having CNS metastases, 12%
in the CTI and 30% in the CDI arm (two-sided test, alpha-level:
5%). Analysis was performed on an intention to treat basis. In the
two arms, patients should be followed until CNS relapse or death
and for a follow-up period of at least 1 year.
Time to CNS metastases was the primary endpoint of the study
and was defined as the time from randomisation to the radiological
occurrence of CNS failure. The cumulative incidence of CNS
metastases was estimated using a competing risk analysis,
accounting for death resulting from all causes as a competing
risk. To compare treatment groups, the Gray’s test was used (Gray,
1988).
PFS and OS were analysed as secondary end points. PFS was
defined as the time from randomisation to any type of progression
or death from any cause. OS was defined as the time from
randomisation to death from any cause. Both end points were
estimated by means of the Kaplan–Meier method and the log-rank
test was used for comparisons.
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sTo assess safety, the two arms were compared in terms of all
grade distribution using the Wilcoxon’s rank-sum test. Difference
in occurrence of grade 3/4 toxicity events between arms was
assessed using the Fisher’s exact test.
All P-values were based on a two-sided test and statistical
analyses were carried out using SAS statistical software (Release
9.1; SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
From June 2003 to June 2007, 150 patients with unresectable stage
IV melanoma were randomly assigned by 12 Italian centres to
receive either CTI (n¼75) or CDI (n¼75) (Figure 1). One patient
in the CTI arm was excluded due to CNS metastases at
randomisation.
Patients and known prognostic factors were well balanced in the
two arms (Table 1). Fifty-three percent of the patients had stage
M1c, 29% had an elevated serum LDH and 32% had received
adjuvant therapy, consisting almost exclusively of high-dose
interferon.
CNS failure
CNS failure was assessable in 118 patients, 57 in the CTI and 61 in
the CDI arm. Of the 118 patients, 58 were positive at brain CT scan,
24 in the CTI and 34 in the CDI arm. The remaining 31 patients
died after a median period of 3 months before CNS failure
evaluation and of these, 13 died before undergoing any instru-
mental assessment of disease.
Figure 2 shows the cumulative incidence of the CNS metastases
among patients treated with CTI and CDI. Death without CNS
metastases was considered a competing event. The observed risk of
a CNS relapse with CTI was not significantly different to that with
CDI (P¼0.22, Gray’s test).
The 1-year cumulative CNS failure incidence was 20.6% for the
CTI and 31.1% for the CDI, and the cause specific hazard ratio
(HR) for CTI vs CDI was 0.9 (95% CI: 0.5, 1.5).
CNS metastases represented the first site of failure for 32
patients (12 in the CTI and 20 in the CDI arm) and for 26 patients
the CNS relapse was preceded by a failure in another site.
Ten patients are still alive after a minimum follow-up of 46
months: four with CNS metastases, three with metastases in other
sites and three in complete remission.
The clinical characteristics of CNS progressions did not differ in
the two arms: 14 patients had a single lesion, six in the CTI and
eight in the CDI arm, and 44 had multiple lesions: 18 in the CTI
and 26 in the CDI arm.
Response
The OR rate was 18% in the CTI and 22% in the CDI arm (P¼0.73,
w
2-test). Complete remission occurred in 10 patients (7%), two in
Analysed (n=75)
Analysed (n=74)
Excluded from analysis (n=1)
-CNS metastases at diagnosis
Assessed for eligibility (n=150)
Stratified
-Gender
-Stage (M1a and M1b, M1c)
-Serum LDH (normal, above normal)
-Clinical centre
Lost to follow-up (n=1)
Discontinued CDI (n=49)
-Toxicity (n=1)
-Death/progression (n=46)
-Withdrawal (n=2)
Allocated to CDI (n=75)
-Received CDI (n=74)
-Did not receive CDI (n=1)
-refused treatment
Lost to follow-up (n=0)
Discontinued CTI (n=52)
-Toxicity (n=7)
-Death/progression (n=40)
-Withdrawal (n=5)
Allocated to CTI (n=75)
-Received CTI (n=75)
Randomised (n=150)
Figure 1 CONSORT diagram.
Table 1 Patient characteristics
CDI arm
(N¼75)
CTI arm
(N¼74)
Age, years 54.5 (23–74) 51.2 (23–74)
Sex
Male 46 (61%) 45 (61%)
Female 29 (39%) 29 (39%)
ECOG-PS
0 52 (69%) 51 (69%)
1 15 (20%) 17 (23%)
2 3 (4%) 3 (4%)
Not reported 5 (7%) 3 (4%)
Disease site
M1a–M1b 35 (47%) 35 (47%)
M1c 40 (53%) 39 (53%)
LDH level
Abnormal 22 (29%) 21 (28%)
Normal 53 (71%) 53 (72%)
Time from diagnosis to
metastatic disease, months
32.3 (1.8–164.9) 23.2 (0–159.7)
Abbreviations: CDI¼DTIC-based chemotherapy; CTI¼TMZ-based chemotherapy;
DTIC¼Dacarbazine; ECOG-PS¼Eastern Cooperative Oncology Group perfor-
mance status; LH¼lactate dehydrogenase; TMZ¼Temozolomide. Data are N (%)
or median (range).
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Figure 2 Cumulative incidence function of central nervous system failure
of patients receiving TMZ-based chemotherapy (CTI) and DTIC-based
chemotherapy (CDI).
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sthe CTI and eight in the CDI arm. An additional 30 patients (20%),
16 in the CTI and 14 in the CDI arm, presented SD.
The median PFS (Figure 3) was 4.1 months (95% CI: 3.5–5.4) in
the CTI and 3.9 (95% CI: 2.8–5.1) in the CDI arm (P¼0.90,
log-rank test), and the HR for CTI vs CDI was 1.0 (95% CI: 0.7,
1.4). The 1-year PFS was 13.7% (95% CI: 7.0–22.6) in the CTI and
14.9 (95% CI: 7.9–23.9) in the CDI arm.
The median OS (Figure 4) was 8.4 months (95% CI: 7.0–10.5) in
the CTI and 8.7 (95% CI: 7.3–13.2) in the CDI arm (P¼0.40, log-
rank test), and the HR for CTI vs CDI was 1.2 (95% CI: 0.8, 1.6).
The 1-year OS was 31.2% (95% CI: 20.8–42.0) in the CTI and
41.9% (95% CI: 30.6–52.8) in the CDI arm.
In patients with CNS failure, the median OS was 13.5 months
(95% CI: 9.3–19.1) for the CTI and 11.5 (95% CI: 8.1–14.4) for the
CDI arm (Figure 5, P¼0.25, log-rank test), and the HR for CTI vs
CDI was 0.7 (95% CI: 0.4,1.3).
Safety
In the CTI arm, 22 patients (30%) completed the planned
treatment and 52 stopped earlier, 7 (9%) for toxicity and 45
(61%) for PD, death or refusal. In the CDI arm, 26 patients (35%)
completed the planned treatment and 49 stopped earlier, 1 for
toxicity (1%) and 48 (64%) for PD, death or refusal. The mean
delivered doses of cisplatin and IL-2 were the same in the two
arms: 47mgm
 2 and 30 MU; 40 and 41 patients received G-CSF in
the CTI and CDI arm, respectively.
Treatment was carried out almost entirely on an outpatient basis
and patients were admitted only for disease palliation. No
treatment-related deaths were observed. Haematological and
non-haematological toxicities are summarised in Table 2. Haema-
tological and flu-like symptoms were the most frequently observed
toxicities in both arms, followed by nausea/vomit and liver enzyme
abnormalities. The distribution of all grade toxicity was similar in
the two groups, except for anaemia, which was higher in the CTI
arm (P¼0.01, Wilcoxon’s rank-sum test).
DISCUSSION
This is the first prospective study designed to test whether TMZ is
able to decrease the incidence and alter the clinical course of CNS
metastases in melanoma patients. When we planned this trial in
2001, bio-chemotherapy was still considered a promising approach
able to produce objective tumour responses in up to 40% of treated
patients. As a high activity was crucial for the purpose of our
study, we chose to compare TMZ and DTIC not alone but in
combination with cisplatin and IL-2 (Eton et al, 2002).
The clinical activity observed in the two arms is similar to that
published using these combinations (Bafaloukos et al, 2005;
Gonzalez Cao et al, 2006; Wierzbicka-Hainaut et al, 2010). The
incidence of CNS failure in the CDI arm was as expected and
consistent with our previous experience using dacarbazine alone
or in combination. Instead, the incidence in the CTI arm was
higher than planned and previously published, particularly in
responsive patients where it reached 60%. This finding can be
explained by the specific design of the study where CNS imaging
every 4 months detected asymptomatic CNS metastases in more
than 50% of patients. Neither the incidence of CNS recurrences nor
the clinical course of the CNS involvement were significantly
influenced by TMZ. In fact, the percentage of single or multiple
lesions, as well as the overall survival in patients with CNS relapses
and the incidence of CNS failure as first site of metastasis, were
similar in the two arms. The significant reduction reported by Paul
et al (2002) was observed in a retrospective analysis of different
studies where the CNS relapses were not specifically sought-after
and the radiological confirmation of clinical suspicion was not
mandatory. Likewise, no specific follow-up, aimed at detecting
asymptomatic lesions, was reported in the study by Ron et al
(2006), where no CNS recurrences were observed in 10 responding
1.00
0.75
0.50
0.25
P
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
s
u
r
v
i
v
a
l
0.00
0 6 12 18 24 30 36 42 48 54 60
1 2 2 2 2
Months
2 2 4 11 24 75 CDI
Patients at risk
CTI 74 26 11 4 1 1 1 1 ....
Figure 3 Kaplan–Meier curves for progression-free survival of patients
receiving TMZ-based chemotherapy (CTI) and DTIC-based chemotherapy
(CDI).
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Figure 4 Kaplan–Meier curves for overall survival of patients receiving
TMZ-based chemotherapy (CTI) and DTIC-based chemotherapy (CDI).
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Figure 5 Kaplan–Meier curves for overall survival of patients with
central nervous system failure receiving TMZ-based chemotherapy (CTI)
and DTIC-based chemotherapy (CDI).
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spatients. Weber et al (2005), although declaring the analysis was
not planned in advance, reported a significant reduction from 33
to 6% in CNS failure, as first site of recurrence, comparing a TMZ
bio-chemotherapy combination with patients previously treated
with a DTIC bio-chemotherapy regimen. Instead, when a brain
imaging follow-up was planned, as in the phase II trial by Gonzalez
Cao et al (2006) where brain MRI was carried out every 3 months,
the CNS failure rate observed with a TMZ schedule was similar to
that observed with a DTIC regimen. A high percentage of CNS
recurrences (10 out of 28 patients) has also recently been reported
by Wierzbicka-Hainaut et al (2010), in a phase II study with
cisplatin and TMZ. Besides the drawbacks of being either phase II
or retrospective, all these studies seem to indicate that CNS failure
is more related to the modality and timing to detect it, than to the
regimen used. Moreover, considering or not the early progressions
in other visceral sites as competitive with the CNS failures could
influence the results.
This study was powered to detect an absolute 18% reduction of
CNS failure as expected from previous phase II studies (Atkins
et al, 2002; Paul et al, 2002), therefore we can not exclude that a
larger study could be statistically significant. However, in our
opinion, the main reason for the inefficacy or low efficacy in
preventing or significantly delaying the CNS recurrence is related
to the low systemic activity of TMZ and all chemotherapy
combinations in metastatic melanoma. Our study highlights that
patients who developed CNS metastases did not have a worse
prognosis than other patients progressing in other sites and
represent 40% of long-survivors. Therefore, we firmly believe that
CNS metastases should not be an exclusion criterion for new
investigational studies.
In the early stage of the CNS metastasis process, the BBB is a key
point. In established CNS metastases there is disruption and
leakiness of the BBB due to hydrostatic pressure, tumour size and
ischaemia. Therefore, when the lesions are well established, the
specific activity of the drug is crucial to obtain a clinical effect.
Different tumour types have different BBB permeability depending
on tumour cell expression or secretion of specific molecules
(Cordon-Cardo et al, 1990; Toth et al, 1996). Thus, in order to
decrease CNS progression in melanoma patients, we need drugs
with a greater systemic activity, able to cross the BBB and active in
the CNS growing metastatic cells (Gerstner and Fine, 2007).
A more successful control of systemic disease with a drug unable
to cross the BBB and not effective in CNS metastases, could lead to
an increase in the CNS failures (Ono et al, 2009). The increased
incidence of CNS metastases in breast cancer patients treated with
trastuzumab (Bendell et al, 2003), supports this concept.
Considering our findings and all these aspects, we believe that
any new drug with some activity in melanoma should be evaluated
also for its effect on CNS metastasis incidence. Owing to the high
propensity of melanoma cells to metastasise to the brain, drugs
unable to reach or ineffective in this site, risk having a limited
impact on the clinical course of the disease.
Even if the reliability of our results could be questioned by the
small sample size, the global and 1-year incidence of CNS
metastases in melanoma patients is not significantly reduced by
TMZ in combination with cisplatin and IL-2 vs the same
combination with DTIC. We believe that this failure should be
ascribed to the low systemic activity of this combination and to the
high propensity of melanoma to develop CNS metastases.
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Temozolomide impact on melanoma central nervous system failure
V Chiarion-Sileni et al
1820
British Journal of Cancer (2011) 104(12), 1816–1821 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sBafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P,
Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G,
Christodoulou C, Kouroussis C, Iconomou T, Gogas H (2005)
Temozolomide and cisplatin versus temozolomide in patients with
advanced melanoma: a randomized phase II study of the Hellenic
Cooperative Oncology Group. Ann Oncol 16(6): 950–957
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG,
Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters
KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson
JA, Thompson JF (2001) Final version of the American Joint Committee
on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):
3635–3648
Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE
(2004) Incidence proportions of brain metastases in patients diagnosed
(1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.
J Clin Oncol 22(14): 2865–2872
Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I,
Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system
metastases in women who receive trastuzumab-based therapy for
metastatic breast carcinoma. Cancer 97(12): 2972–2977
Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic
melanoma: an overview. Oncology (Williston Park) 23(6): 488–496
Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R,
Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U,
Statkevich P, Von Hoff DD, Eckhardt SG (1999) A Phase I and
pharmacokinetic study of temozolomide and cisplatin in patients with
advanced solid malignancies. Clin Cancer Res 5(7): 1629–1637
Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR
(1990) Expression of the multidrug resistance gene product
(P-glycoprotein) in human normal and tumor tissues. J Histochem
Cytochem 38(9): 1277–1287
D’Atri S, Graziani G, Lacal PM, Nistico V, Gilberti S, Faraoni I, Watson AJ,
Bonmassar E, Margison GP (2000) Attenuation of O(6)-methylguanine-
DNA methyltransferase activity and mRNA levels by cisplatin and
temozolomide in jurkat cells. J Pharmacol Exp Ther 294(2): 664–671
E t o nO ,L e g h aS S ,B e d i k i a nA Y ,L e eJ J ,B u z a i dA C ,H o d g e sC ,R i n gS E ,
Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS (2002) Sequential
biochemotherapy versus chemotherapy for metastatic melanoma: results
from a phase III randomized trial. JC l i nO n c o l20(8): 2045–2052
Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain
barrier to chemotherapy in metastatic brain tumors: establishing a
treatment paradigm. J Clin Oncol 25(16): 2306–2312
Gonzalez Cao M, Malvehy J, Marti R, Conill C, Sanchez M, Martin M,
Carrera C, Herrero J, Gascon P, Mellado B, Castel T, Puig S (2006)
Biochemotherapy with temozolomide, cisplatin, vinblastine, subcuta-
neous interleukin-2 and interferon-alpha in patients with metastatic
melanoma. Melanoma res 16(1): 59–64
Gray RJ (1988) A class of k-sample tests for comparing the cumulative
incidence of a competing risk. Ann Stat 16: 1141–1154
Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas
NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR,
Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson
JA, Trisal V, Urist MM, Walker MJ (2006) Melanoma. J Natl Compr Canc
Netw 4(7): 666–684
Ives NJ, Stowe RL, Lorigan P, Wheatley K (2007) Chemotherapy compared
with biochemotherapy for the treatment of metastatic melanoma:
a meta-analysis of 18 trials involving 2,621 patients. JC l i nO n c o l25(34):
5426–5434
Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S,
Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D,
Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000)
Randomized phase III study of temozolomide versus dacarbazine in the
treatment of patients with advanced metastatic malignant melanoma.
J Clin Oncol 18(1): 158–166
Ono M, Ando M, Yunokawa M, Nakano E, Yonemori K, Matsumoto K,
Kouno T, Shimizu C, Tamura K, Katsumata N, Fujiwara Y (2009) Brain
metastases in patients who receive trastuzumab-containing chemother-
apy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol
14(1): 48–52
Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH, Thatcher N,
Middleton MR (2002) Effect of temozolomide on central nervous
system relapse in patients with advanced melanoma. Melanoma res
12(2): 175–178
Piccioni D, D’Atri S, Papa G, Caravita T, Franchi A, Bonmassar E, Graziani
G (1995) Cisplatin increases sensitivity of human leukemic blasts to
triazene compounds. J Chemother 7(3): 224–229
Ready N, Aronson F, Wanebo H, Kennedy T (2005) A low rate of
central nervous system progression in a phase II trial of outpatient
chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and
interferon alfa 2-B for metastatic malignant melanoma. Am J Clin Oncol
28(5): 479–484
Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A,
Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O (2002) Cisplatin,
dacarbazine with or without subcutaneous interleukin-2, and interferon
alpha-2b in advanced melanoma outpatients: results from an
Italian multicenter phase III randomized clinical trial. J Clin Oncol
20(6): 1600–1607
Ridolfi R, Romanini A, Sileni VC, Michiara M, Guida M, Biasco G, Poletti P,
Amaducci L, Leoni M, Ravaioli A (2004) Temozolomide and interferon-
alpha in metastatic melanoma: a phase II study of the Italian Melanoma
Intergroup. Melanoma res 14(4): 295–299
Ron IG, Sarid D, Ryvo L, Sapir EE, Schneebaum S, Metser U, Asna N, Inbar
MJ, Safra T (2006) A biochemotherapy regimen with concurrent
administration of cisplatin, vinblastine, temozolomide (Temodal),
interferon-alfa and interleukin-2 for metastatic melanoma: a phase II
study. Melanoma res 16(1): 65–69
Toth K, Vaughan MM, Peress NS, Slocum HK, Rustum YM (1996) MDR1
P-glycoprotein is expressed by endothelial cells of newly formed
capillaries in human gliomas but is not expressed in the neovasculature
of other primary tumors. Am J Pathol 149(3): 853–858
Weber RW, O’Day S, Rose M, Deck R, Ames P, Good J, Meyer J, Allen R,
Trautvetter S, Timmerman M, Cruickshank S, Cook M, Gonzalez R,
Spitler LE (2005) Low-dose outpatient chemobiotherapy with temozo-
lomide, granulocyte-macrophage colony stimulating factor, interferon-
alpha2b, and recombinant interleukin-2 for the treatment of metastatic
melanoma. J Clin Oncol 23(35): 8992–9000
Wen PY, Black PM, Loeffler JS (2001) Treatment of metastatic cancer. In
Cancer: Principles & Practice of Oncology DeVita Jr VT, Hellman S,
Rosenberg SA (eds) 6th edn, pp 2655–2670. Lippincott, Williams &
Wilkins: Philadelphia, PA
Wierzbicka-Hainaut E, Sassolas B, Mourey L, Guillot B, Bedane C, Guillet G,
Tourani JM (2010) Temozolomide and cisplatin combination in naive
patients with metastatic cutaneous melanoma: results of a phase II
multicenter trial. Melanoma res 20(2): 141–146
This work is licensed under the Creative Commons
Attribution-NonCommercial-Share Alike 3.0 Unported
License. To view a copy of this license, visit http://creativecommons.
org/licenses/by-nc-sa/3.0/
Temozolomide impact on melanoma central nervous system failure
V Chiarion-Sileni et al
1821
British Journal of Cancer (2011) 104(12), 1816–1821 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s